Algernon Pharmaceuticals (AGNPF) Projected to Post Quarterly Earnings on Monday

Algernon Pharmaceuticals (OTCMKTS:AGNPF) is projected to issue its results after the market closes on Monday, April 27th. Analysts expect the company to announce earnings of ($0.4976) per share for the quarter.

Algernon Pharmaceuticals Trading Up 785.6%

Shares of Algernon Pharmaceuticals stock opened at $0.32 on Friday. Algernon Pharmaceuticals has a 52 week low of $0.02 and a 52 week high of $0.07. The firm’s 50 day moving average is $0.05 and its two-hundred day moving average is $0.05.

About Algernon Pharmaceuticals

Algernon Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel, small-molecule therapeutics. The company’s primary strategy centers on repurposing known compounds with established safety profiles to address unmet medical needs, particularly in the realms of pulmonary fibrosis, acute lung injury and central nervous system (CNS) disorders. By leveraging existing pharmacology data, Algernon aims to accelerate its development timelines while managing costs and risks typically associated with early-stage drug discovery.

The lead asset in Algernon’s pipeline is NP-120 (ifenprodil), an orally available small molecule being investigated for idiopathic pulmonary fibrosis (IPF).